Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.
Feature|Slideshows|June 17, 2025
Physician Survey Results: Primary Care Knowledge of Screening for Cognitive Decline
Author(s)Sydney Jennings
Fact checked by: Grace Halsey
New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.
Advertisement
Advertisement
As the number of aging adults expands and rates of cognitive decline rise, primary care clinicians will remain the first point of contact for detection and early management—so how prepared do they feel for this role? A new survey of US primary care clinicians conducted by Patient Care© offers a snapshot of current attitudes, practices, and knowledge related to cognitive assessment in the clinical setting and familiarity with standard-of-care medications.
Related to this article
FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Advertisement
Advertisement